No profile data available.
Serina Therapeutics, Inc. (SER) is a healthcare company in the antiviral pharmaceuticals industry, based in Huntsville, United States, with about 16 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$19.18 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $50.80 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Serina Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$50.80 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Vaxart, Inc. (VXRT), Verrica Pharmaceuticals Inc. (VRCA), Kalaris Therapeutics, Inc. (KLRS), Tevogen Bio Holdings Inc. (TVGN).